Speaker articles
Take a look at what some of our Cell-NCI Symposium: Beyond Cancer Genomics Toward Precision Oncology speakers have published recently.
Speakers
Andrea Califano, Columbia University, USA
A modular master regulator landscape controls cancer transcriptional identity
Christina Curtis, Stanford University, USA
Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases
Daniel De Carvalho, Princess Margaret Cancer Centre, Canada
DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells
Mathew Garnett, Wellcome Sanger Institute (WSI), UK
Minimal genome-wide human CRISPR-Cas9 library
William Hahn, Dana-Farber Cancer Institute (DFCI), USA
STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells
Cigall Kadoch, Broad Institute/Dana-Farber Cancer Institute (DFCI), USA
A Structural Model of the Endogenous Human BAF Complex Informs Disease Mechanisms
Xiaole Shirley Liu, Dana-Farber/Harvard Cancer Center, USA
Systematic characterization of mutations altering protein degradation in human cancers
Michael McManus, University of California San Francisco (UCSF), USA
Examining the evidence for extracellular RNA function in mammals
Gordon Mills Oregon Health & Science University (OSHU), USA
Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines
Dana Pe'er, Memorial Sloan Kettering Cancer Centre (MSKCC), USA
Engineering γδT cells limits tonic signaling associated with chimeric antigen receptors
Aviv Regev, Genentech, USA
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma
Eytan Ruppin, National Cancer Institute (NCI), USA
Synthetic lethality-mediated precision oncology via the tumor transcriptome
Stuart Schreiber, Broad Institute/Harvard University, USA
Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles
Louis Staudt, National Cancer Institute (NCI), USA
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
Itay Tirosh, Weizmann Institute of Science, Israel
Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity
Olga Troyanskaya, Princeton University, USA
Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies
Samra Turajlic, The Institute of Cancer Research, UK
Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study
Jeffrey Tyner, Oregon Health and Science University (OHSU), USA
Ex Vivo Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics
Jonathan Weissman, Whitehead Institute, USA
Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts
